{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:17:56Z","timestamp":1778620676247,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jcv.2020.104285","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:33:58Z","timestamp":1580124838000},"page":"104285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9426-2869","authenticated-orcid":false,"given":"Ashly E.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Wyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Schackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0010","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2055-6640(20)30264-8","article-title":"Report from the International Viral Hepatitis Elimination meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework","volume":"4","author":"Popping","year":"2018","journal-title":"J. Virus Erad."},{"issue":"18","key":"10.1016\/j.jcv.2020.104285_bib0020","first-page":"465","article-title":"State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs - United States, 2015\u20132016","volume":"66","author":"Campbell","year":"2017","journal-title":"MMWR"},{"issue":"17","key":"10.1016\/j.jcv.2020.104285_bib0025","first-page":"453","article-title":"Increases in hepatitis C virus infection related to injection drug use among persons aged <\/=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012","volume":"64","author":"Zibbell","year":"2015","journal-title":"MMWR"},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0030","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104285_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2015.12.026","article-title":"Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study","volume":"160","author":"Carlson","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jcv.2020.104285_bib0040","series-title":"Guidance on Community Viral Load: A Family of Measures, Definitions, and Method for Calculation","author":"Centers for Disease Control and Prevention","year":"2011"},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0045","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3018(16)00019-9","article-title":"Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study","volume":"3","author":"Solomon","year":"2016","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.jcv.2020.104285_bib0050","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/QAD.0000000000000212","article-title":"Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011","volume":"28","author":"Townsend","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/jir747","article-title":"Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples","volume":"205","author":"Hughes","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0060","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1086\/497131","article-title":"Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study","volume":"41","author":"Yazdanpanah","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0065","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","article-title":"Estimating per-act HIV transmission risk: a systematic review","volume":"28","author":"Patel","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/QAD.0b013e32834de5fe","article-title":"Use of the community viral load as a population-based biomarker of HIV burden","volume":"26","author":"Castel","year":"2012","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0075","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/QAI.0b013e31828ed2e4","article-title":"Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004-2011","volume":"63","author":"Das","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"Suppl. 1","key":"10.1016\/j.jcv.2020.104285_bib0080","first-page":"A7","article-title":"Community viral load: a new population-based biomarker of HIV disease burden in Scotland","volume":"92","author":"Ismail","year":"2016","journal-title":"Sex. Transm. Infect."},{"issue":"9740","key":"10.1016\/j.jcv.2020.104285_bib0085","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Expanded HAART coverage is associated with decreased population-level HIV-1-RNA and annual new HIV diagnoses in British Columbia, Canada","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"issue":"9740","key":"10.1016\/j.jcv.2020.104285_bib0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0140-6736(10)60936-1","article-title":"Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study","volume":"376","author":"Montaner","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcv.2020.104285_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011068","article-title":"Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco","volume":"5","author":"Das","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0100","first-page":"26","article-title":"Monitored viral load: a measure of HIV treatment outcomes in an outpatient setting in Rhode Island","volume":"98","author":"Touzard Romo","year":"2014","journal-title":"RI Med. J. (2013)"},{"key":"10.1016\/j.jcv.2020.104285_bib0105","doi-asserted-by":"crossref","first-page":"b1649","DOI":"10.1136\/bmj.b1649","article-title":"Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study","volume":"338","author":"Wood","year":"2009","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jcv.2020.104285_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053284","article-title":"Measuring population transmission risk for HIV: an alternative metric of exposure risk in men who have sex with men (MSM) in the US","volume":"7","author":"Kelley","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jcv.2020.104285_bib0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(12)70314-6","article-title":"Community viral load as a measure for assessment of HIV treatment as prevention","volume":"13","author":"Miller","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"13","key":"10.1016\/j.jcv.2020.104285_bib0120","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/QAD.0b013e328360f619","article-title":"Disparities in community viral load among HIV-infected persons in New York City","volume":"27","author":"Laraque","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1468-0009.2012.00678.x","article-title":"Who and what is a \u201cpopulation\u201d? Historical debates, current controversies, and implications for understanding \u201cpopulation health\u201d and rectifying health inequities","volume":"90","author":"Krieger","year":"2012","journal-title":"Milbank Q."},{"issue":"2\u20133","key":"10.1016\/j.jcv.2020.104285_bib0130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/10550887.2015.1059111","article-title":"Can HIV and Hepatitis C virus infection be eliminated among persons who inject Drugs?","volume":"34","author":"Perlman","year":"2015","journal-title":"J. Addict. Dis."},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-0031-1297923","article-title":"HCV routes of transmission: what goes around comes around","volume":"31","author":"Alter","year":"2011","journal-title":"Semin. Liver Dis."},{"issue":"17","key":"10.1016\/j.jcv.2020.104285_bib0140","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","article-title":"Incidence of sexually transmitted hepatitis C virus infection in HIV-positive MSM: a systematic review and meta-analysis","volume":"29","author":"Hagan","year":"2015","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0145","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0150","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","article-title":"The natural history of hepatitis C virus infection: host, viral, and environmental factors","volume":"284","author":"Thomas","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute Hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0160","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drugalcdep.2008.08.017","article-title":"High dead-space syringes and the risk of HIV and HCV infection among injecting drug users","volume":"100","author":"Zule","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"7104","key":"10.1016\/j.jcv.2020.104285_bib0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/bmj.315.7104.333","article-title":"Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus","volume":"315","author":"Dore","year":"1997","journal-title":"BMJ."},{"issue":"6","key":"10.1016\/j.jcv.2020.104285_bib0170","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/hep.20938","article-title":"Hepatitis C virus load and survival among injection drug users in the United States","volume":"42","author":"Hisada","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/650298","article-title":"SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and\/or human immunodeficiency virus","volume":"31","author":"Henderson","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"issue":"5","key":"10.1016\/j.jcv.2020.104285_bib0180","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00006454-200101000-00003","article-title":"Prospective study of mother-to-infant transmission of hepatitis C virus","volume":"20","author":"Tajiri","year":"2001","journal-title":"Pediatric Infect Dis J."},{"issue":"12","key":"10.1016\/j.jcv.2020.104285_bib0190","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/infdis\/jir654","article-title":"Agent, host, and environment: hepatitis C virus in people who inject drugs","volume":"204","author":"Hagan","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.jcv.2020.104285_bib0195","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104285_bib0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst. Rev."},{"issue":"9760","key":"10.1016\/j.jcv.2020.104285_bib0205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(10)60903-8","article-title":"An international registry of systematic-review protocols","volume":"377","author":"Booth","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2020.104285_bib0210","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0215","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/QAI.0b013e318263a111","article-title":"Is total community viral load a robust predictive marker of the efficacy of the TasP strategy?","volume":"61","author":"Henard","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0220","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S2352-3018(16)00036-9","article-title":"Community viral load as an index of HIV transmission potential","volume":"3","author":"Herbeck","year":"2016","journal-title":"Lancet HIV"},{"issue":"March (6)","key":"10.1016\/j.jcv.2020.104285_bib0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/QAD.0000000000000602","article-title":"High HIV prevalence and incidence among MSM across 12 cities in India","volume":"29","author":"Solomon","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2020.104285_bib0230","series-title":"British Columbia Drug Overdose and Alert Partnership Report Provincial Health Services Authority","author":"British Columbia Centre for Disease Control","year":"2014"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0235","first-page":"S377","article-title":"Hepatitis C virus genotypes: an association with viral loads","author":"Zaffar","year":"2013","journal-title":"Hepatol. Int."},{"issue":"11","key":"10.1016\/j.jcv.2020.104285_bib0240","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/BF01691224","article-title":"Relationship between viral genotype and viral load in patients with chronic hepatitis C","volume":"15","author":"Garcia","year":"1996","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0245","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/003655202760373461","article-title":"Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin","volume":"37","author":"Carlsson","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0250","first-page":"A57","article-title":"Factors influencing response of chronic hepatitis C to peginterferon and ribavirin therapy","author":"Agarwala","year":"2014","journal-title":"Ind. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0255","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/S0168-8278(11)60784-8","article-title":"Hepatic miRNA signature predicting sustained virological response in chronic hepatitis C","author":"Estrabaud","year":"2011","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0260","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1016\/S0168-8278(10)61074-4","article-title":"ITMN-191\/R7227 monotherapy in chronic HCV patients reduces plasma concentrations of IP-10 and neopterin","author":"Schaefer","year":"2010","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.jcv.2020.104285_bib0265","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/JVI.80.6.2654-2664.2006","article-title":"Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients","volume":"80","author":"Eren","year":"2006","journal-title":"J. Vir."},{"issue":"8","key":"10.1016\/j.jcv.2020.104285_bib0270","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.guideline","article-title":"Recommendations for the clinical management of hepatitis C in Iran: a consensus-based national guideline","volume":"16","author":"Alavian","year":"2016","journal-title":"Hepat. Mon."},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0275","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1155\/2015\/591260","article-title":"Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: implications for access to care and elimination strategies in Canada","volume":"29","author":"Borgia","year":"2015","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jcv.2020.104285_bib0280","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1023\/A:1010697319589","article-title":"Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C","volume":"46","author":"Adinolfi","year":"2001","journal-title":"Digest. Dis. Sci."},{"issue":"5","key":"10.1016\/j.jcv.2020.104285_bib0285","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c","volume":"34","author":"Poynard","year":"2001","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0290","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2011.06.005","article-title":"Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users","volume":"119","author":"Boodram","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"9055","key":"10.1016\/j.jcv.2020.104285_bib0295","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0300","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.1999.tb00018.x","article-title":"Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels","volume":"19","author":"Puoti","year":"1999","journal-title":"Liver"},{"issue":"9956","key":"10.1016\/j.jcv.2020.104285_bib0305","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.jcv.2020.104285_bib0310","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"New Eng. J. Med."},{"issue":"25","key":"10.1016\/j.jcv.2020.104285_bib0315","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"New Eng. J. Med."},{"issue":"13","key":"10.1016\/j.jcv.2020.104285_bib0320","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jcv.2020.104285_bib0325","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104285_bib0330","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejogrb.2015.09.009","article-title":"Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers","volume":"194","author":"Garcia-Tejedor","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"5","key":"10.1016\/j.jcv.2020.104285_bib0335","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1440-1746.2002.02601.x","article-title":"Different outcomes of vertical transmission of hepatitis C virus in a twin pregnancy","volume":"17","author":"Inui","year":"2002","journal-title":"J. Gastroentrol. Hepatol."},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0340","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv089","article-title":"Hepatitis C virus (HCV) vertical transmission in 12-month-old infants born to HCV-infected women and assessment of maternal risk factors","volume":"2","author":"Jhaveri","year":"2015","journal-title":"Open Forum Infect. Dis."},{"issue":"7","key":"10.1016\/j.jcv.2020.104285_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention","volume":"9","author":"Wiessing","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0350","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2893.2010.01279.x","article-title":"Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents","volume":"18","author":"Grebely","year":"2011","journal-title":"J. Viral Hepat."},{"issue":"3","key":"10.1016\/j.jcv.2020.104285_bib0355","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MEG.0b013e32832a8c4c","article-title":"Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support","volume":"22","author":"Grebely","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jcv.2020.104285_bib0360","first-page":"S334","article-title":"Implementing a dried blood spot testing algorithm including HCV RNA to determine the prevalence HCV among injecting drug users","volume":"7","author":"Catlett","year":"2013","journal-title":"Hepatol. Int."},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0365","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/S095026880500498X","article-title":"Analysis of a hepatitis C screening programme for US veterans","volume":"134","author":"Zuniga","year":"2006","journal-title":"Epidemiol. Infect."},{"issue":"6","key":"10.1016\/j.jcv.2020.104285_bib0370","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2105\/AJPH.2013.301827","article-title":"Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study","volume":"104","author":"Frimpong","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"11","key":"10.1016\/j.jcv.2020.104285_bib0375","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2105\/AJPH.2014.302142","article-title":"Risk factors for HCV infection among young adults in Rural New York who inject prescription opioid analgesics","volume":"104","author":"Zibbell","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"5","key":"10.1016\/j.jcv.2020.104285_bib0380","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/hep.23885","article-title":"Frequent multiple hepatitis C virus infections among injection drug users in a prison setting","volume":"52","author":"Pham","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0385","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1016\/S0168-8278(10)60669-1","article-title":"Early detection of hepatitis C using a one minute visual qualitative based kit system in a community based setting in Doha, Qatar","author":"Sharma","year":"2010","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jcv.2020.104285_bib0390","first-page":"250","article-title":"HIV and hepatitis C and associated risks among injecting drug users in Germany-preliminary results from two pilot studies 2011 using respondent driven sampling","volume":"15","author":"Zimmermann","year":"2013","journal-title":"Suchtmedizin Forschung Praxis"},{"issue":"1","key":"10.1016\/j.jcv.2020.104285_bib0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029679","article-title":"Novel use of surveillance data to detect HIV-infected persons with sustained high viral load and durable virologic suppression in New York City","volume":"7","author":"Terzian","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0400","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ije\/dyr194","article-title":"Where science meets policy: comparing longitudinal and cross-sectional designs to address diarrhoeal disease burden in the developing world","volume":"41","author":"Markovitz","year":"2012","journal-title":"Int. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.jcv.2020.104285_bib0405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/hiv.12219","article-title":"Impact of defined clinical population and missing data on temporal trends in HIV viral load estimation within a health care system","volume":"16","author":"Edelman","year":"2015","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2020.104285_bib0410","series-title":"Neighborhoods and Health","author":"Kawachi","year":"2003"},{"key":"10.1016\/j.jcv.2020.104285_bib0415","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sste.2013.04.004","article-title":"How to choose geographical units in ecological studies: proposal and application to campylobacteriosis","volume":"7","author":"Arsenault","year":"2013","journal-title":"Spat. Spatio-Temp. Epidemiol."},{"issue":"2","key":"10.1016\/j.jcv.2020.104285_bib0420","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11869-011-0140-9","article-title":"Confounding and exposure measurement error in air pollution epidemiology","volume":"5","author":"Sheppard","year":"2012","journal-title":"Air Qual. Atmos. Health"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:11:52Z","timestamp":1761361912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653220300275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":84,"alternative-id":["S1386653220300275"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104285","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104285"}}